Business Wire

SpeeDx Develops Multiplex Test for Respiratory Viruses

Del

SpeeDx Pty. Ltd. today announced submission of their PlexPCR® RespiVirus test to the Therapeutic Goods Administration (TGA). The company anticipates clearance in time for the Australian 2019 flu season. The test utilises SpeeDx market-leading PlexPCR® multiplex technology, designed for detection of 14 targets representing 10 viral respiratory-illness causing pathogens.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190212006006/en/

SpeeDx PlexPCR RespiVirus offers excellent sensitivity and improved productivity for fast and reprod ...

SpeeDx PlexPCR RespiVirus offers excellent sensitivity and improved productivity for fast and reproducible respiratory virus testing. (Graphic: Business Wire)

“We are excited to expand our infectious disease portfolio into the respiratory market,” said Colin Denver, SpeeDx CEO. “SpeeDx patented technology enables multiple targets to be easily combined into a single test, which means laboratories can get results for more patients over the course of a work day compared to standard technologies. This is particularly important during the peak respiratory-testing seasons when laboratories are resource challenged.”

The SpeeDx PlexPCR RespiVirus test detects major respiratory pathogens including Influenza A, Influenza B, Rhinoviruses (A & B), Respiratory Syncytial Viruses (A & B), Human metapneumovirus, Adenoviruses, and Human parainfluenza viruses 1, 2, 3 and 4. The impact of these respiratory pathogens is seen most heavily during late winter-early spring, with combined health and economic impacts attributed to absenteeism, hospitalisation, and serious complications leading to admission in intensive care, and in some instances death. The most severe health risks are attributed to influenza illness in infants, elderly, and immune-compromised people.1 The 2017 Australian Flu season was particularly severe with over 233,453 reported cases of influenza (2.5 x the number reported in 2016), with almost 30,000 hospital admissions and 745 deaths – higher than any previous year to date.2

The anticipated addition of PlexPCR RespiVirus will add to SpeeDx’s infectious disease test portfolio that includes PlexPCR® VHS, a multiplex lesion diagnostic test for Herpes Viruses (Type-1 & -2); Varicella Zoster Virus, responsible for causing chicken pox and shingles; and Treponema pallidum, the bacterium that causes syphilis. Other tests in the SpeeDx portfolio specialise in sexually transmitted infections (STIs) and genetic mutations for antibiotic resistance. Tests include ResistancePlus® MG – clinically proven to improve cure rates for patients infected with the STI Mycoplasma genitalium (Mgen) by using antibiotic resistance information included in the test result.3 SpeeDx also markets ResistancePlus® GC (CE-IVD)* - the first commercial test to detect Neisseria gonorrhoeae, the bacterium causing gonorrhoea, and genetic markers for ciprofloxacin susceptibility, enabling doctors to treat patients with an inexpensive and simple oral antibiotic.

*not available in the U.S. or A.U.

About Respiratory Viruses

Respiratory tract infections (RTIs) are responsible for the majority of primary health care consults,4 causing high morbidity and mortality, particularly in young, elderly or immune-compromised populations.5 Viral agents cause up to 90% of RTIs - mainly human rhinoviruses (RhV), influenza viruses, and respiratory syncytial virus (RSV).6 Symptoms and duration include: common cold, sinusitis, pharyngitis, epiglottitis, and laryngotracheitis.7

Bacterial infection is difficult to establish without performing diagnostic tests, thus empirical use of antibiotics is discouraged in treatment guidelines.8-12 Most uncomplicated infections will clear within 2-5 days without medical intervention.13,14 However, accurate detection of respiratory viruses is important in patient care, guiding therapy and infection control measures.15 Most importantly, distinguishing bacterial RTIs from viral is essential to avoid unnecessary antibiotic prescription. Pathogen identification is also a key component in management of acute respiratory infection outbreaks and pandemic preparedness strategies.15,16

About PlexPCR®

PlexPCR® kits are highly multiplexed qPCR tests for detection of infectious diseases. Powered by proprietary PlexZyme® and PlexPrime® technologies, the product line offers high multiplexing capability for better, more streamlined infectious disease management, and improved laboratory workflow.

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see https://plexpcr.com

References

  1. http://www.who.int/mediacentre/factsheets/fs211/en/
  2. Australian Government. 2017 Influenza Season in Australia. Information Brief (22 November 2017).
  3. Read T R H, et al. CID 68(4): 554-560.
  4. Office of Population Censuses and Surveys. Series MB5,3. London: HMSO,1995
  5. http://www.erswhitebook.org/chapters/the-burden-of-lung-disease/
  6. Brittain-Long et al. Scand J Infect Dis 44(1):9-17
  7. https://www.ncbi.nlm.nih.gov/books/NBK8142/
  8. U.S. Department of Health and Human Services. Research Protocol – May 23, 2014 (Update)
  9. Harris AM et al. Annals of Int. Med. 164(6):425-435.
  10. https://www.nice.org.uk/guidance/CG69
  11. Woodhead et al. CMI 2011;17(6):1–24.
  12. Mahony JB. Clin. Microbiol. Rev. 2008;21(4):716–747
  13. Harris AM et al. Annals of Internal Medicine 164(6):425-435.
  14. https://www.nice.org.uk/guidance/CG69
  15. Ginocchio, CC & McAdam AJ. J Clin Micro. 2011; 49(9): S44–S48
  16. https://www.gov.uk/government/publications/acute-respiratory-infections-investigating-outbreaks-and-clusters-in-schools

Contact information

Madeline O’Donoghue
SpeeDx Global Marketing Manager
madelineo@speedx.com.au
+61 406 582 808

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

New Enforce Tac Exhibitor Meggitt Training Systems to Exhibit Portable, Small-Arms Simulator19.2.2019 09:00:00Pressemelding

Meggitt Training Systems will conduct demonstrations of its FATS® 100P portable simulator during its first visit to Enforce Tac (stand 12-129) on March 6-7, 2019, in Nuremberg, Germany. Leveraging key features from the US Army Engagement Skills Trainer II and US Marine Corps Indoor Simulated Marksmanship Trainer programs of record, the industry-leading FATS 100P delivers a significant expansion in virtual small-arms training capability and is ideally suited for use by European law enforcement departments. “As tactical law enforcement challenges evolve, Meggitt is leveraging in-house expertise and customer feedback to expand its line of simulators from the immersive FATS 300 and 180 to the portable 100P,” said Matt Cunningham, Meggitt’s director of virtual systems sales. “Enforce Tac visitors to our stand can learn more, especially how the FATS 100P facilitates training resource sharing among units, as well as enables field deployment for easy set-up in a room that’s not a dedicated tra

ABB Wins $42 Million Order for Train Technologies from Indian Railways19.2.2019 08:30:00Pressemelding

ABB has won its largest traction equipment order in India, worth more than $42 million to supply state-of-the-art converters for electric locomotives from Diesel Locomotive Works (DLW), in Varanasi. The converters are custom designed for Indian Railways and will be manufactured at one of ABB’s largest factories for locomotive applications in Nelamangala, near Bengaluru, in Southern India. ABB’s traction solution is based on the latest technology to bring more reliable trains to passengers, while increasing sustainable transport use by moving from diesel trains to electric. This helps rail operators to achieve significant operational improvements. “We are delighted to be contributing to the electrification of India’s rail network with ABB’s locally manufactured solutions,” said ABB CEO Ulrich Spiesshofer. “By adopting advanced technologies, India is achieving rapid improvements in growth and productivity and shaping its economy for the era of digitalization.” “We are privileged to work

Exclusive Group Further Advances Global VAD Reach with Acquisition of SecureWave in Israel19.2.2019 08:06:00Pressemelding

Exclusive Group, the value-added services and technologies (VAST) group, today announced it is acquiring SecureWave, one of Israel’s leading independent cybersecurity VADs. The move adds another advanced economy to the worldwide market penetration of the Exclusive Group, establishes an in-country presence within one of the world’s most significant innovation hubs, and expands the Group’s service reach to the benefit of its global customers and partners. “This acquisition is about more than just filling in the gaps of our EMEA footprint – it represents a fantastic opportunity to tap into a significant new local market and use our in-country presence to extend relationships with Israeli-based technology innovators,” said Olivier Breittmayer, CEO at Exclusive Group. “In SecureWave we feel we have identified a like-minded VAD business with a committed and successful team who understand value. And as well as similar business principles, we also share some of the same cybersecurity and cloud

The O-RAN Alliance Announces New Open Fronthaul Specification, Demos and Industry Event at Mobile World Congress 201919.2.2019 08:00:00Pressemelding

The O-RAN Alliance announced today that it will be releasing the first O-RAN standard Open Fronthaul Specifications comprised of control, user, synchronization and management plane protocols. Sachin Katti, Stanford University Professor and O-RAN TSC co-chair said, “we are excited to release the first O-RAN Open Fronthaul Specification. O-RAN has leveraged significant specification work done in xRAN and will accelerate interoperability testing and product commercialization. Further, the O-RAN fronthaul workgroup has also started discussions on potential new study items to pursue for 2019.” An O-RAN industry event will kick off the MWC activities on Monday February 25th at 6:00pm, hosted by Deutsche Telekom on its stage in Hall 3. Following this event, O-RAN Alliance members will showcase six strategic proof-of-concepts across various member booths covering four key themes: intelligent RAN control, Open Interfaces, virtualization and white box. Chih-Lin I, China Mobile Chief Scientist an

Gain Therapeutics SA Announces Closing of EU 2.5 Million Series A Financing to Develop Novel Brain-Penetrant Non-Competitive Pharmacological Chaperones for Rare Lysosomal Storage Diseases and CNS Indications19.2.2019 07:30:00Pressemelding

GT Gain Therapeutics SA today announces that it has closed a €2.5 Million series A financing with VitaTech S.A. (€1.1Mio), Helsinn Investment Fund S.A. (€1Mio), and with existing investor TiVenture S.A. (€0.4). Gain Therapeutics SA is a private company, based in Lugano (Switzerland) and with a branch in Barcelona, that exclusively licensed an advanced computational technology (Site-directed Enzyme Enhancement Therapy, SEE-Tx®) used to identify next generation brain-penetrant non-competitive pharmacological chaperones. SEE-Tx® applicable to all diseases with a known genetic mutation in target proteins, allows the identification of brain-penetrant small molecules that provide a gain-of-function of misfolded proteins. Gain Therapeutics has already identified molecules for the treatment of a group of metabolic disorders called lysosomal storage disorders and some chronic degenerative diseases of the nervous system. Prof. Xavier Barril (CSO) commented: “The closing of this first part of ser

Australia Emerges as a Leading Innovator for Agriculture 4.019.2.2019 05:30:00Pressemelding

Australia’s long and distinguished history in agricultural research is cementing its position as a global hub for agriculture and food technology. Driven by a variety of climates and ecosystems, a stable and favourable business environment, and connectivity with the rapidly growing markets of Asia, Australia is capitalising on these advantages to become a centre for agtech and foodtech innovation. Australia for Agriculture 4.0, a new initiative by Austrade, the nation’s trade and investment promotion agency, will build on the country’s impressive record in agricultural innovation to facilitate foreign investment, exports and collaboration in both agtech and foodtech. The initiative aims to establish Australia as a global hub for agricultural and food innovation. It will showcase Australia’s agtech and foodtech capability, and highlight its unique technological advances, research excellence, strong record of innovation expertise, as well as the nation’s strong government support and est